AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes

Reuters

2025/05/15

<a href="https://laohu8.com/S/ABCL">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes

AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535880618"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535880618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535880618?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535880618","market":"us","top_or_hot":-1,"title":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL1QmYsZ:1","article_id":"2535880618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535880618","pubTimestamp":1747256467,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor  and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms  associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics","BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓"},"translate_title":"AbCellera Biologics Inc.获得加拿大卫生部ABCL635治疗更年期潮热的1期试验授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    \n\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}